TRU-016, a Small Modular ImmunoPharmaceutical (SMIP^TM) protein therapeutic, is a novel CD37-directed therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia, or CLL, as well as certain autoimmune and inflammatory disease indications.

TRU-016 is currently in clinical development for CLL. We are also exploring other cancer and autoimmune indications for this molecule.

We have a worldwide strategic collaboration with Trubion Pharmaceuticals for the joint development, manufacture and commercialization of protein therapeutics directed against the CD37 antigen, including TRU-016.